Concepts (244)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Skin Neoplasms | 14 | 2024 | 546 | 4.690 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 2023 | 1077 | 1.310 |
Why?
|
| Dermatology | 5 | 2022 | 35 | 1.160 |
Why?
|
| Mohs Surgery | 4 | 2022 | 21 | 1.140 |
Why?
|
| Carcinoma, Basal Cell | 2 | 2023 | 54 | 1.140 |
Why?
|
| Dermatologic Surgical Procedures | 2 | 2017 | 16 | 1.110 |
Why?
|
| Botulinum Toxins, Type A | 4 | 2021 | 49 | 1.100 |
Why?
|
| Neuromuscular Agents | 3 | 2021 | 25 | 1.020 |
Why?
|
| Skin | 6 | 2022 | 554 | 0.940 |
Why?
|
| Dermatitis Herpetiformis | 2 | 2011 | 9 | 0.800 |
Why?
|
| Tissue Embedding | 1 | 2020 | 6 | 0.770 |
Why?
|
| Histiocytoma, Benign Fibrous | 1 | 2020 | 25 | 0.760 |
Why?
|
| Wnt Signaling Pathway | 1 | 2020 | 94 | 0.710 |
Why?
|
| Laser Therapy | 3 | 2017 | 142 | 0.690 |
Why?
|
| Cosmetic Techniques | 3 | 2021 | 28 | 0.680 |
Why?
|
| beta Catenin | 1 | 2020 | 255 | 0.660 |
Why?
|
| Melanoma | 1 | 2022 | 459 | 0.640 |
Why?
|
| Chemexfoliation | 1 | 2017 | 3 | 0.620 |
Why?
|
| Dermabrasion | 1 | 2017 | 3 | 0.620 |
Why?
|
| Isotretinoin | 1 | 2017 | 23 | 0.620 |
Why?
|
| Carcinoma in Situ | 1 | 2018 | 53 | 0.620 |
Why?
|
| Immunotherapy | 1 | 2022 | 631 | 0.600 |
Why?
|
| Regenerative Medicine | 1 | 2017 | 24 | 0.590 |
Why?
|
| Neoplasm Proteins | 1 | 2020 | 532 | 0.590 |
Why?
|
| Dermatologic Agents | 1 | 2017 | 71 | 0.570 |
Why?
|
| Patient Safety | 1 | 2017 | 211 | 0.510 |
Why?
|
| Sweet Syndrome | 1 | 2014 | 5 | 0.500 |
Why?
|
| Dapsone | 2 | 2011 | 10 | 0.500 |
Why?
|
| Humans | 41 | 2024 | 86656 | 0.500 |
Why?
|
| Cellulitis | 1 | 2014 | 19 | 0.500 |
Why?
|
| Stem Cells | 1 | 2017 | 358 | 0.500 |
Why?
|
| Videotape Recording | 1 | 2014 | 47 | 0.490 |
Why?
|
| Internship and Residency | 3 | 2022 | 1010 | 0.480 |
Why?
|
| Psoriasis | 2 | 2014 | 240 | 0.460 |
Why?
|
| Botulinum Toxins | 1 | 2021 | 17 | 0.410 |
Why?
|
| Skin Diseases, Papulosquamous | 1 | 2011 | 5 | 0.410 |
Why?
|
| Churg-Strauss Syndrome | 1 | 2011 | 9 | 0.400 |
Why?
|
| Panniculitis | 1 | 2011 | 8 | 0.390 |
Why?
|
| Tachycardia, Supraventricular | 1 | 2011 | 16 | 0.390 |
Why?
|
| Hair | 2 | 2010 | 56 | 0.380 |
Why?
|
| Prostatic Neoplasms | 1 | 2022 | 1721 | 0.380 |
Why?
|
| Loose Anagen Hair Syndrome | 1 | 2010 | 5 | 0.380 |
Why?
|
| Hypothermia, Induced | 1 | 2011 | 74 | 0.370 |
Why?
|
| Biopsy | 3 | 2023 | 1163 | 0.370 |
Why?
|
| Dermatitis | 1 | 2010 | 32 | 0.360 |
Why?
|
| Malnutrition | 1 | 2010 | 34 | 0.360 |
Why?
|
| Practice Guidelines as Topic | 4 | 2020 | 1037 | 0.330 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2014 | 931 | 0.330 |
Why?
|
| Clinical Competence | 1 | 2014 | 756 | 0.330 |
Why?
|
| Evidence-Based Medicine | 2 | 2020 | 429 | 0.300 |
Why?
|
| Keratinocytes | 3 | 2006 | 144 | 0.270 |
Why?
|
| Neurotoxins | 2 | 2015 | 49 | 0.250 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2024 | 16 | 0.240 |
Why?
|
| Oncogene Protein p21(ras) | 1 | 2003 | 6 | 0.230 |
Why?
|
| Skin Diseases | 2 | 2017 | 165 | 0.220 |
Why?
|
| Male | 14 | 2022 | 40995 | 0.220 |
Why?
|
| Prospective Studies | 5 | 2023 | 4212 | 0.220 |
Why?
|
| Antineoplastic Agents | 1 | 2014 | 2360 | 0.220 |
Why?
|
| Neoplasm Invasiveness | 3 | 2018 | 552 | 0.220 |
Why?
|
| Methylation | 1 | 2023 | 251 | 0.210 |
Why?
|
| Paget Disease, Extramammary | 1 | 2022 | 8 | 0.210 |
Why?
|
| Prognosis | 3 | 2022 | 3681 | 0.210 |
Why?
|
| Female | 14 | 2022 | 44566 | 0.200 |
Why?
|
| Rubber | 1 | 2020 | 6 | 0.190 |
Why?
|
| Adhesives | 1 | 2020 | 4 | 0.190 |
Why?
|
| Immunohistochemistry | 2 | 2018 | 1759 | 0.190 |
Why?
|
| Margins of Excision | 1 | 2020 | 39 | 0.190 |
Why?
|
| Societies, Medical | 2 | 2022 | 573 | 0.190 |
Why?
|
| Molecular Targeted Therapy | 1 | 2022 | 266 | 0.190 |
Why?
|
| Cohort Studies | 3 | 2023 | 2765 | 0.180 |
Why?
|
| Adenocarcinoma, Sebaceous | 1 | 2019 | 2 | 0.180 |
Why?
|
| Sebaceous Gland Neoplasms | 1 | 2019 | 4 | 0.180 |
Why?
|
| Middle Aged | 10 | 2019 | 25027 | 0.180 |
Why?
|
| Lichen Sclerosus et Atrophicus | 1 | 2019 | 7 | 0.170 |
Why?
|
| NF-kappa B | 1 | 2003 | 447 | 0.170 |
Why?
|
| Papilloma | 1 | 2019 | 22 | 0.170 |
Why?
|
| RNA | 1 | 2023 | 561 | 0.170 |
Why?
|
| Treatment Outcome | 6 | 2015 | 7982 | 0.170 |
Why?
|
| Aged, 80 and over | 4 | 2018 | 6511 | 0.160 |
Why?
|
| Immunocompetence | 1 | 2018 | 27 | 0.160 |
Why?
|
| Lipectomy | 1 | 2017 | 9 | 0.160 |
Why?
|
| Platelet-Rich Plasma | 1 | 2017 | 10 | 0.150 |
Why?
|
| Cicatrix | 1 | 2017 | 63 | 0.150 |
Why?
|
| Immunocompromised Host | 1 | 2018 | 140 | 0.150 |
Why?
|
| Diagnosis, Differential | 2 | 2011 | 1564 | 0.150 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2017 | 180 | 0.140 |
Why?
|
| Adipocytes | 1 | 2017 | 155 | 0.140 |
Why?
|
| Aged | 9 | 2022 | 18407 | 0.140 |
Why?
|
| Follow-Up Studies | 5 | 2015 | 3639 | 0.130 |
Why?
|
| Injections | 2 | 2021 | 108 | 0.130 |
Why?
|
| Preservation, Biological | 1 | 2015 | 4 | 0.130 |
Why?
|
| Drug Storage | 1 | 2015 | 3 | 0.130 |
Why?
|
| Peripheral Nervous System Neoplasms | 1 | 2015 | 19 | 0.130 |
Why?
|
| Darier Disease | 1 | 2015 | 4 | 0.130 |
Why?
|
| Drug Contamination | 1 | 2015 | 12 | 0.130 |
Why?
|
| Tissue Engineering | 1 | 2017 | 181 | 0.130 |
Why?
|
| Eyebrows | 1 | 2015 | 10 | 0.130 |
Why?
|
| Ear, External | 1 | 2015 | 26 | 0.130 |
Why?
|
| Lasers, Solid-State | 1 | 2015 | 8 | 0.130 |
Why?
|
| Low-Level Light Therapy | 1 | 2015 | 15 | 0.130 |
Why?
|
| Chickenpox | 1 | 2015 | 39 | 0.130 |
Why?
|
| Exanthema | 1 | 2015 | 36 | 0.120 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2014 | 29 | 0.120 |
Why?
|
| Pandemics | 1 | 2020 | 737 | 0.120 |
Why?
|
| Standard of Care | 1 | 2015 | 79 | 0.120 |
Why?
|
| Fibroblasts | 1 | 2017 | 731 | 0.120 |
Why?
|
| Viscosupplements | 1 | 2013 | 5 | 0.120 |
Why?
|
| Forehead | 1 | 2013 | 15 | 0.120 |
Why?
|
| Cetuximab | 1 | 2014 | 113 | 0.120 |
Why?
|
| Leg | 1 | 2014 | 137 | 0.120 |
Why?
|
| Skin Aging | 1 | 2013 | 28 | 0.120 |
Why?
|
| Hyaluronic Acid | 1 | 2013 | 48 | 0.120 |
Why?
|
| Vacuum Curettage | 1 | 2013 | 5 | 0.110 |
Why?
|
| Abnormalities, Multiple | 1 | 2015 | 232 | 0.110 |
Why?
|
| Hyperhidrosis | 1 | 2013 | 10 | 0.110 |
Why?
|
| Consensus | 1 | 2015 | 336 | 0.110 |
Why?
|
| Blood Loss, Surgical | 1 | 2013 | 112 | 0.110 |
Why?
|
| Operating Rooms | 1 | 2014 | 126 | 0.110 |
Why?
|
| Neutrophils | 1 | 2014 | 308 | 0.110 |
Why?
|
| Needles | 1 | 2012 | 35 | 0.110 |
Why?
|
| Microinjections | 1 | 2012 | 70 | 0.110 |
Why?
|
| Surgical Wound Infection | 1 | 2013 | 182 | 0.100 |
Why?
|
| Recurrence | 1 | 2014 | 1139 | 0.100 |
Why?
|
| Serologic Tests | 1 | 2011 | 41 | 0.100 |
Why?
|
| Immunoglobulin A | 1 | 2011 | 80 | 0.100 |
Why?
|
| Neurotransmitter Agents | 1 | 2021 | 106 | 0.100 |
Why?
|
| Diet, Gluten-Free | 1 | 2011 | 52 | 0.100 |
Why?
|
| Face | 1 | 2021 | 114 | 0.100 |
Why?
|
| Biopsy, Needle | 1 | 2011 | 234 | 0.100 |
Why?
|
| Drug Delivery Systems | 1 | 2012 | 178 | 0.090 |
Why?
|
| Anti-Infective Agents | 1 | 2011 | 90 | 0.090 |
Why?
|
| Physical Examination | 1 | 2011 | 149 | 0.090 |
Why?
|
| Combined Modality Therapy | 1 | 2014 | 1686 | 0.090 |
Why?
|
| Microscopy | 1 | 2010 | 87 | 0.090 |
Why?
|
| Drug Administration Schedule | 1 | 2011 | 915 | 0.090 |
Why?
|
| Hypothyroidism | 1 | 2011 | 232 | 0.090 |
Why?
|
| Immunoglobulin G | 1 | 2011 | 457 | 0.090 |
Why?
|
| Severity of Illness Index | 2 | 2013 | 1804 | 0.090 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2011 | 261 | 0.080 |
Why?
|
| Transcription Factor AP-2 | 2 | 2006 | 14 | 0.080 |
Why?
|
| Time Factors | 2 | 2015 | 5215 | 0.080 |
Why?
|
| Patient Care Team | 1 | 2011 | 280 | 0.080 |
Why?
|
| Celiac Disease | 1 | 2011 | 203 | 0.080 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 2704 | 0.080 |
Why?
|
| Comorbidity | 1 | 2011 | 945 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2011 | 1960 | 0.070 |
Why?
|
| Retrospective Studies | 2 | 2018 | 8476 | 0.070 |
Why?
|
| Adult | 6 | 2015 | 25648 | 0.070 |
Why?
|
| Infant, Newborn | 1 | 2011 | 2380 | 0.060 |
Why?
|
| Single-Blind Method | 2 | 2015 | 153 | 0.060 |
Why?
|
| Phenotype | 1 | 2010 | 2389 | 0.060 |
Why?
|
| Child, Preschool | 1 | 2010 | 3612 | 0.060 |
Why?
|
| NF-KappaB Inhibitor alpha | 1 | 2003 | 41 | 0.060 |
Why?
|
| I-kappa B Proteins | 1 | 2003 | 53 | 0.060 |
Why?
|
| ErbB Receptors | 1 | 2006 | 486 | 0.050 |
Why?
|
| Equipment Design | 2 | 2015 | 406 | 0.050 |
Why?
|
| Private Practice | 1 | 2022 | 11 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2011 | 2272 | 0.050 |
Why?
|
| Young Adult | 4 | 2015 | 5977 | 0.050 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2022 | 68 | 0.050 |
Why?
|
| Animals | 5 | 2011 | 26706 | 0.050 |
Why?
|
| Patient Care | 1 | 2022 | 100 | 0.050 |
Why?
|
| Cell Division | 1 | 2003 | 696 | 0.050 |
Why?
|
| Trans-Activators | 1 | 2003 | 430 | 0.050 |
Why?
|
| DNA-Binding Proteins | 2 | 2003 | 1214 | 0.050 |
Why?
|
| Emergencies | 1 | 2020 | 113 | 0.050 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2002 | 269 | 0.050 |
Why?
|
| Cell Differentiation | 2 | 2003 | 1471 | 0.050 |
Why?
|
| Curriculum | 1 | 2022 | 542 | 0.040 |
Why?
|
| Deoxycholic Acid | 1 | 2017 | 10 | 0.040 |
Why?
|
| Mesotherapy | 1 | 2017 | 2 | 0.040 |
Why?
|
| Cryotherapy | 1 | 2017 | 29 | 0.040 |
Why?
|
| Photography | 1 | 2017 | 37 | 0.040 |
Why?
|
| Ultrasonic Therapy | 1 | 2017 | 32 | 0.040 |
Why?
|
| Mice | 4 | 2006 | 11439 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2006 | 3267 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2022 | 2502 | 0.030 |
Why?
|
| Keratins | 2 | 2006 | 63 | 0.030 |
Why?
|
| Gloves, Surgical | 1 | 2013 | 6 | 0.030 |
Why?
|
| Injections, Intradermal | 1 | 2013 | 19 | 0.030 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2013 | 23 | 0.030 |
Why?
|
| Self-Assessment | 1 | 2013 | 47 | 0.030 |
Why?
|
| Diagnostic Imaging | 1 | 2017 | 468 | 0.030 |
Why?
|
| Universities | 1 | 2013 | 135 | 0.030 |
Why?
|
| Axilla | 1 | 2013 | 99 | 0.030 |
Why?
|
| Comparative Effectiveness Research | 1 | 2013 | 53 | 0.030 |
Why?
|
| Administration, Cutaneous | 1 | 2012 | 58 | 0.030 |
Why?
|
| Urban Population | 1 | 2013 | 214 | 0.030 |
Why?
|
| Technology, Pharmaceutical | 1 | 2012 | 30 | 0.030 |
Why?
|
| Wound Healing | 1 | 2013 | 345 | 0.020 |
Why?
|
| Ambulatory Care Facilities | 1 | 2012 | 103 | 0.020 |
Why?
|
| Adolescent | 2 | 2015 | 8988 | 0.020 |
Why?
|
| Pharmaceutical Preparations | 1 | 2012 | 92 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 2 | 2006 | 943 | 0.020 |
Why?
|
| Incidence | 1 | 2015 | 1578 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2013 | 407 | 0.020 |
Why?
|
| Mice, Transgenic | 2 | 2006 | 1557 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2013 | 747 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2012 | 1824 | 0.020 |
Why?
|
| Tyrphostins | 1 | 2006 | 7 | 0.020 |
Why?
|
| Chromones | 1 | 2006 | 28 | 0.020 |
Why?
|
| Skin Abnormalities | 1 | 2006 | 11 | 0.020 |
Why?
|
| Hair Diseases | 1 | 2006 | 9 | 0.020 |
Why?
|
| Dermis | 1 | 2006 | 27 | 0.020 |
Why?
|
| Transforming Growth Factor alpha | 1 | 2006 | 50 | 0.020 |
Why?
|
| Ki-67 Antigen | 1 | 2006 | 64 | 0.020 |
Why?
|
| Integrases | 1 | 2006 | 60 | 0.020 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2006 | 137 | 0.020 |
Why?
|
| Morpholines | 1 | 2006 | 65 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2006 | 159 | 0.020 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2006 | 135 | 0.020 |
Why?
|
| Epidermal Growth Factor | 1 | 2006 | 119 | 0.020 |
Why?
|
| Caspases | 1 | 2006 | 155 | 0.020 |
Why?
|
| Epidermis | 1 | 2006 | 101 | 0.020 |
Why?
|
| Gene Expression Regulation | 2 | 2006 | 1928 | 0.020 |
Why?
|
| Embryo, Mammalian | 1 | 2006 | 219 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2006 | 193 | 0.020 |
Why?
|
| Animals, Newborn | 1 | 2006 | 516 | 0.020 |
Why?
|
| Quinazolines | 1 | 2006 | 220 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2006 | 323 | 0.020 |
Why?
|
| Hair Follicle | 1 | 2003 | 27 | 0.010 |
Why?
|
| GATA3 Transcription Factor | 1 | 2003 | 48 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2006 | 1106 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2015 | 3366 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2006 | 639 | 0.010 |
Why?
|
| Sp2 Transcription Factor | 1 | 2002 | 1 | 0.010 |
Why?
|
| Keratin-5 | 1 | 2002 | 3 | 0.010 |
Why?
|
| Keratin-15 | 1 | 2002 | 3 | 0.010 |
Why?
|
| Sp1 Transcription Factor | 1 | 2002 | 19 | 0.010 |
Why?
|
| Deoxyribonuclease I | 1 | 2002 | 28 | 0.010 |
Why?
|
| Sebaceous Glands | 1 | 2002 | 28 | 0.010 |
Why?
|
| Skin Transplantation | 1 | 2003 | 172 | 0.010 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 2002 | 173 | 0.010 |
Why?
|
| Gene Expression | 1 | 2006 | 1286 | 0.010 |
Why?
|
| United States | 1 | 2013 | 6674 | 0.010 |
Why?
|
| Calcium | 1 | 2006 | 1156 | 0.010 |
Why?
|
| DNA | 1 | 2006 | 1295 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2006 | 1596 | 0.010 |
Why?
|
| Binding Sites | 1 | 2002 | 1104 | 0.010 |
Why?
|
| Base Sequence | 1 | 2002 | 2335 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2002 | 1138 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2002 | 3035 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2002 | 2839 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2002 | 1580 | 0.010 |
Why?
|